Heart failure and transplantation with Dr Ileana Piņa

View all posts »

Heart-failure trials to look for at AHA 2010

Nov 10, 2010 16:35 EST


Watch out for the following top trials in heart failure at the AHA Scientific Sessions 2010:

1.      Benefits of Natriuretic Peptide Guided Heart Failure Therapy for Patients With Chronic Left Ventricular Systolic Dysfunction: Primary Results of the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study, presented by Dr Jim Januzzi on Monday, November 15, 2010 at 9:45 AM

2.      Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF), presented by Dr Adrian Hernandez on Sunday, November 14 at 4:51PM

3.      The Effect of Eplerenone versus Placebo on Cardiovascular Mortality or Heart Failure Hospitalization in Subjects with NYHA Class II Chronic Systolic Heart Failure (EMPHASIS-HF), presented by Dr Faiez Zannad on Sunday, November 14 at 4:29 PM

See:

Late-breaking clinical trials at AHA 2010

What's going to be hot at AHA 2010





« Previous Post
Petitioning the Social Security Administration for compassionate disability for HF, transplant, and congenital heart-disease patients
Nov 16, 2010 15:30 EST Next post »
Collaborative care in heart-failure patients
Oct 20, 2010 15:25 EDT



Your comments
Heart-failure trials to look for at AHA 2010
# 1 of 2
November 18, 2010 04:52 (EST)
Alex

Dr. Pina,

I saw one of your posts on the role on education and its impact on readmission and overall costs reduction compared to other interventions. I cannot find that information on your blog. Could you help me find the name of the study?

Thank you and thank you for your great blog. It is very informative and above all, useful.

Alex

# 2 of 2
December 23, 2010 09:26 (EST)
Dr Franchi Marcelo

 

Estimada Dr. Pina.

Soy medico Residente de cardiologia de Hospital en Buenos Aires. Argentina. Mi intencion es Hacer ICC insuficiencia cardiacay transplante.

He presntado recientmente en la residencia de mi hospital eL trabajo EFESUS HF pacientes con ICC CF II con FEY <30. Esplerenona.

Mi pregunta es alicable la espironolactona en este tipo de pacintes. He escuchado su charla con Dr Fuster en The HEART/ . Probablmente se considere esta droga Indicacion CLASE 1A.

Desde ya muchas gracias.

Dr MARCELO FRANCHI


You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Forgot your username and/or password?
        Login        
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

    Join now for full access    
About Dr Ileana Piņa
Dr Piņa is Associate Vice Chief for Academic Affairs, Albert Einstein College of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, New York.